Perceptive Informatics Appoints Head of Cardiology and Nuclear Medicine to Its Medical Imaging Group

BOSTON, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has appointed Vladimir Evilevitch, M.D., Ph.D., to the position of Associate Medical Director and Head of Cardiology and Nuclear Medicine in its Medical Imaging Group.  Dr. Evilevitch, formerly a Regional Medical Advisor at Novartis Healthcare, will support the continued expansion of Perceptive's expertise in cardiovascular imaging modalities and capabilities to advise clients on the use of imaging in cardiology trials to make earlier safety and efficacy assessments about their compounds.

At Novartis Healthcare, Dr. Evilevitch worked in the fields of oncology medical affairs and clinical development. He formerly served as a Chief Attending Physician in the Diagnostic Imaging Division at Malmoe University Hospital in Sweden, where he was responsible for cardiac imaging interpretation for clinical care.  Dr. Evilevitch has extensive experience in several imaging modalities, including cardiac Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), as well as Multi Gated Acquisition Scan (MUGA), echocardiography, and others.  As a Visiting Scientist at the National Institutes of Health (NIH) he worked in cardiovascular translational medicine with micro-Computed Tomography (CT) applications.  Dr. Evilevitch received his M.D. and Ph.D. degrees from the Lund University in Sweden.  He completed his post doctoral fellowship at the University of California, Los Angeles (UCLA) in the Department of Molecular and Medical Pharmacology, Nuclear Medicine Clinic.  Dr. Evilevitch is author of several peer-reviewed scientific publications in the fields of physiology and oncology.  His work has been recognized by the Swedish Society of Medicine and American Society of Clinical Oncology (ASCO).

"Perceptive is extremely pleased to have Dr. Evilevitch join our team of medical imaging experts. We believe that his experience in international biopharmaceutical development and nuclear imaging modalities will help to expand our capabilities to effectively guide our clients in their imaging-based trials," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics.  "Our goal is to assist clients in making better decisions about their compounds in order to bring new safe and effective treatments to patients sooner."

Experts from the Perceptive Informatics Medical Imaging Group will be available at the American Heart Association Scientific Sessions, being held November 14-16 in Chicago, Illinois, to discuss Perceptive's capabilities to support imaging-based cardiology trials.  Experts at the Perceptive Booth #2428 in the exhibit hall will demonstrate leading image processing and analysis tools and proprietary image management applications. Perceptive experts will also address advantages of centralized, global cardiovascular review services.

The Medical Imaging Group of Perceptive Informatics offers a full range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including cardiology, oncology, neurology, rheumatology, and endocrinology. Perceptive's sophisticated medical imaging technologies are fully validated, and rigorously designed to achieve high data quality. For more information about Perceptive Informatics, visit: www.perceptive.com.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170  employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation